Literature DB >> 10818603

Plasma cell-free Epstein-Barr virus DNA quantitation in patients with nasopharyngeal carcinoma. Correlation with clinical staging.

Y M Lo1, S F Leung, L Y Chan, K W Lo, J Zhang, A T Chan, J C Lee, N M Hjelm, P J Johnson, D P Huang.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10818603     DOI： 10.1111/j.1749-6632.2000.tb06597.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN： 0077-8923            Impact factor:   5.691


× No keyword cloud information.
  30 in total

1.  Serologic biomarkers of Epstein-Barr virus correlate with TNM classification according to the seventh edition of the UICC/AJCC staging system for nasopharyngeal carcinoma.

Authors:  Peng Sun; Cui Chen; Yi-Kan Cheng; Zhi-Jian Zeng; Xin-Lin Chen; Li-Zhi Liu; Mo-Fa Gu
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-11-09       Impact factor: 2.503

Review 2.  The evolution of nasopharyngeal carcinoma staging.

Authors:  Rui Guo; Yan-Ping Mao; Ling-Long Tang; Lei Chen; Ying Sun; Jun Ma
Journal:  Br J Radiol       Date:  2019-07-12       Impact factor: 3.039

Review 3.  Cell-free nucleic acids as biomarkers in cancer patients.

Authors:  Heidi Schwarzenbach; Dave S B Hoon; Klaus Pantel
Journal:  Nat Rev Cancer       Date:  2011-05-12       Impact factor: 60.716

4.  Levels of plasma Epstein-Barr virus DNA prior and subsequent to treatment predicts the prognosis of nasopharyngeal carcinoma.

Authors:  Fei-Peng Zhao; Xiong Liu; Xiao-Mei Chen; Juan Lu; Bo-Long Yu; Wen-Dong Tian; L U Wang; Xia Xu; Hao-Ran Huang; Meng-Wen Zhang; Gang Li; Xiang-Ping Li
Journal:  Oncol Lett       Date:  2015-08-24       Impact factor: 2.967

5.  Circulating human papillomavirus DNA as a marker for disease extent and recurrence among patients with oropharyngeal cancer.

Authors:  Kristina R Dahlstrom; Guojun Li; Caroline S Hussey; Jenny T Vo; Qingyi Wei; Chong Zhao; Erich M Sturgis
Journal:  Cancer       Date:  2015-06-19       Impact factor: 6.860

6.  Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial.

Authors:  Jennifer A Kanakry; Hailun Li; Lan L Gellert; M Victor Lemas; Wen-son Hsieh; Fangxin Hong; King L Tan; Randy D Gascoyne; Leo I Gordon; Richard I Fisher; Nancy L Bartlett; Patrick Stiff; Bruce D Cheson; Ranjana Advani; Thomas P Miller; Brad S Kahl; Sandra J Horning; Richard F Ambinder
Journal:  Blood       Date:  2013-02-05       Impact factor: 22.113

7.  Role of Epstein-Barr virus DNA measurement in plasma in the clinical management of nasopharyngeal carcinoma in a low risk area.

Authors:  J S Kalpoe; P B Douwes Dekker; J H J M van Krieken; R J Baatenburg de Jong; A C M Kroes
Journal:  J Clin Pathol       Date:  2006-02-17       Impact factor: 3.411

8.  Elevated high-sensitivity C-reactive protein levels predict decreased survival for nasopharyngeal carcinoma patients in the intensity-modulated radiotherapy era.

Authors:  Lin Quan Tang; Dong Peng Hu; Qiu Yan Chen; Lu Zhang; Xiao Ping Lai; Yun He; Yun-Xiu-Xiu Xu; Shi-Hua Wen; Yu-Tuan Peng; Wen-Hui Chen; Shan-Shan Guo; Li-Ting Liu; Chao-Nan Qian; Xiang Guo; Mu-Sheng Zeng; Hai-Qiang Mai
Journal:  PLoS One       Date:  2015-04-13       Impact factor: 3.240

9.  Current and emerging treatment options for nasopharyngeal carcinoma.

Authors:  Daniel E Spratt; Nancy Lee
Journal:  Onco Targets Ther       Date:  2012-10-23       Impact factor: 4.147

10.  Radiological, pathological and DNA remission in recurrent metastatic nasopharyngeal carcinoma.

Authors:  Stephen L Chan; Edwin P Hui; Sing F Leung; Anthony T C Chan; Brigette B Y Ma
Journal:  BMC Cancer       Date:  2006-10-31       Impact factor: 4.430
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.